Teva to Market Parkinson’s Drug in China for Lundbeck

H Lundbeck A/S, a pharmaceutical company headquartered in Denmark, expanded its Asian sales agreement with Teva Pharma to include Azilect (rasagiline), a treatment for Parkinson’s disease. The agreement gives Teva the right to market Azilect in China and five other Asian countries. Lundbeck will be responsible for conducting clinical trials of the drug and obtaining SFDA approval. More details... Stock Symbols: (CPH: LUN) (NSDQ: TEVA)